Abstracts tagged "Uric Acid, Urate"

Abstract Number: 1998 • ACR Convergence 2025
Reduction in Tophi Observed in Patients with Uncontrolled Gout Treated with NASP: Results from Phase 3 DISSOLVE Studies
Herbert Baraf¹, Puja Khanna², Frédéric Lioté³, Rehan Azeem⁴, Wesley DeHaan⁵, Ben Peace⁶, Hugues Santin-Janin⁷, Bhavisha Desai⁸ and Alan Kivitz⁹, ¹The Center for Rheumatology and Bone Research, Rheumatology, Wheaton, Maryland, USA; Division of Rheumatology, The George Washington University, Washington, DC, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Université Paris Cité-Inserm UMR¹¹³² & Rheumatology Department, GH Paris Saint Joseph & Institut Arthur Vernes, Paris, France, ⁴Global MACD, Sobi Inc., Waltham, MA, ⁵Sobi, Inc, Waltham, MA, ⁶Statistical Science, Sobi, Stockholm, Sweden, ⁷Sobi, BASEL, Switzerland, ⁸Sobi, Glastonbury, CT, ⁹Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Patients (pts) with uncontrolled gout (UG) and tophi experience joint pain, impaired function and poor quality of life (Schlesinger et al. Semin Arthritis Rheum…
Abstract Number: 1994 • ACR Convergence 2025
Pharmacokinetics of Ready-to-Use Pegloticase Formulation Compared to Standard Pegloticase Dosing: Data from the AGILE Study
Orrin Troum¹, John Botson², Afroz S. Mohammad³, Xiaoqing Yang⁴, Nathan Roe⁵, Supra Verma⁶ and Brian Lamoreaux⁷, ¹Providence Health Care/Doctor's of St John's (MDSJ) Santa Monica, CA, Santa Monica, CA, ²Orthopedic Physicians Alaska, Anchorage, AK, ³Amgen Inc, Deerfield, ⁴Amgen, Seattle, WA, ⁵Horizon Therapeutics, Boise, ID, ⁶Horizon Therapeutics, Newport Beach, CA, ⁷Amgen, Inc., Deerfield, IL
Background/Purpose: Pegloticase is approved for uncontrolled gout as 8-mg infusions admixed in 250 cc of normal saline over 120 minutes or more administered every 2…
Abstract Number: 1992 • ACR Convergence 2025
Tolerance of Methotrexate Coadministered with Pegloticase in Patients with Uncontrolled Gout: Findings from MIRROR RCT
Vinicius Domingues¹, Alexis Woods², Xiaoqing Yang³, Brian Lamoreaux⁴ and Michael Weinblatt⁵, ¹Rheumatology, Allergy, Asthma & Arthritis Center, Daytona beach, FL, ²Amgen, Detroit, MI, ³Amgen, Seattle, WA, ⁴Amgen, Inc., Deerfield, IL, ⁵Brigham and Women's Hospital/ Harvard Medical School, Waban, MA
Background/Purpose: Methotrexate (MTX) coadministered with pegloticase attenuates anti-drug antibody formation, leading to higher response rates and markedly reduced infusion reaction risk compared with pegloticase +…
Abstract Number: 1990 • ACR Convergence 2025
Pilot Study: Testing the Accuracy of a Capillary Point-of-Care Device Compared to Traditional Venous Analysis for Serum Urate Measurements Among Patients with Gout
Alex Tinianow¹, Saiajay Chigurupati¹, Ethan Carey¹, Jiaqi Wang², Sharan Rai³, Gregory Challener⁴, Hyon K. Choi⁵, Philip Riches⁶, Natalie McCormick¹ and Chio Yokose⁷, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, BOston, ³Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁴MGH, Boston, MA, ⁵MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁶NHS Lothian, Edinburgh, UK, Edinburgh, United Kingdom, ⁷Massachusetts General Hospital, Waltham, MA
Background/Purpose: Rheumatology guidelines endorse a treat-to-target (TTT) approach targeting serum urate (SU) < 6 mg/dL among patients with gout who qualify for urate-lowering therapy (ULT).…
Abstract Number: 1991 • ACR Convergence 2025
Co-Use of Mycophenolate Mofetil with Pegloticase Yielded Similar Clinical Outcomes as the Co-Use of Methotrexate
Tingting Zhang¹, Kenneth Saag², Yasir Qazi³, Bradley Marder⁴ and Brian Lamoreaux⁵, ¹Amgen, Inc., Thousand Oaks, ²The University of Alabama at Birmingham, Birmingham, AL, ³Keck School of Medicine Renal Transplant Program, University of Southern California, Los Angeles, CA, ⁴AMGEN, Inc, Denver, CO, ⁵Amgen, Inc., Deerfield, IL
Background/Purpose: Pegloticase significantly reduces serum uric acid (sUA) values in patients with refractory gout. Co-use of methotrexate (MTX) improves efficacy and safety of pegloticase by…
Abstract Number: 1923 • ACR Convergence 2025
A Real-World Survey On Physicians’ Perspectives Of Uncontrolled Gout And Gout Management Practices.
John Botson¹, Menaka Bhor², Nathan Meyer², Molly Edwards³, Emily Goddard³, Victoria Barton⁴ and Jeff Peterson⁵, ¹Orthopedic Physicians of Alaska, Anchorage, AK, ²Sobi Inc, Waltham, MA, ³Adelphi Real World, Bollington, United Kingdom, ⁴Adelphi Real World, Macclesfield, United Kingdom, ⁵Western Washington Arthritis Clinic, Bothell, WA
Background/Purpose: Managing uncontrolled gout (UG) can involve a multi-disciplinary approach involving physicians of different specialities, all of whom may have differing perspectives or approaches for…
Abstract Number: 1139 • ACR Convergence 2025
Synovial Counts, Cultures, and Crystals: An Analysis of 9,000 Aspirations
Sabahat Usmani¹, Gunjan Rana², Shivum Patel¹, Patrick Kennedy¹ and Michael Putman³, ¹Medical College of Wisconsin, Milwaukee, ²Saint Vincent Hospital, Worcester, MA, ³The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Synovial fluid analysis is an essential diagnostic tool for evaluating crystalline and infectious arthritis. Traditionally, a leukocyte count threshold of >50,000 cells/µL has been…
Abstract Number: 1138 • ACR Convergence 2025
Efficacy of Pozdeutinurad (AR882) in Treatment Naïve and Suboptimally Treated Gouty Arthritis with Tophi
Robert Keenan¹, Puja Khanna², Zancong Shen³, Sarah Morris³, Pamela Mundell⁴, Wen Wei⁴, Elizabeth Polvent⁵, Vijay Hingorani⁶, Shunqi Yan⁵ and Li-Tain Yeh⁷, ¹Arthrosi Therapeutics, Raleigh, NC, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Arthrosi therapeutics, San Diego, CA, ⁴Arthrosi Therapeutics Inc, San Diego, CA, ⁵Arthrosi Therapeutics, Inc., San Diego, CA, ⁶Vanguard Healthsciences, Inc., San Diego, CA, ⁷Arthrosi Therapeutics, Inc., Irvine, CA
Background/Purpose: Pozdeutinurad (AR882, POZD) is a novel, selective URAT1 inhibitor currently in phase 3 clinical stage development for the treatment of gout and tophaceous gout.…
Abstract Number: 1130 • ACR Convergence 2025
Novel Anti-Obesity Medications and Serum Urate Change Among Patients with Gout and Baseline Hyperuricemia
Kiara Tan¹, Jiaqi Wang¹, Saiajay Chigurupati², Gregory Challener³, Natalie McCormick¹, Sharan Rai⁴, Florence Porterfield⁵, Chika Anekwe¹, Dong Wook Kim⁶, Fatima Stanford⁷, Caroline Apovian⁸, Hyon K. Choi⁹ and Chio Yokose¹⁰, ¹Massachusetts General Hospital, Boston, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ⁴Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁵Division of Endocrinology, Massachusetts General Hospital, Boston, ⁶Division of Endocrinology, Diabetes and Hypertension, Brigham and Women’s Hospital, Boston, ⁷Neuroendocrine Unit, Pediatric Endocrinology, Massachusetts General Hospital, Boston, ⁸Brigham and Women's Hospital, Boston, ⁹MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ¹⁰Massachusetts General Hospital, Waltham, MA
Background/Purpose: Obesity affects >50% of individuals with gout and is the most important modifiable risk factor for gout. Thus, novel anti-obesity medications (AOM, e.g., semaglutide…
Abstract Number: 1129 • ACR Convergence 2025
Effectiveness of sodium-glucose cotransporter type 2 inhibitors and urate-lowering agents in patients with gout: data from a single-center specialised clinic
Jose Doménech Serrano¹, Ivana García Loiseau², Cristina RodrÍguez-Alvear³, Pablo Riesgo Sanchis¹, Oscar Moreno Pérez¹ and Mariano Andrés¹, ¹Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ²Miguel Hernández University, Alicante, Spain, ³Virgen de la Peña General Hospital, Fuerteventura, Spain
Background/Purpose: Sodium-glucose cotransporter type 2 inhibitors (SGLT2I) proved substantial benefits in diabetes mellitus (DM), heart failure (HF) and kidney disease (KD). In pivotal trials, SGLT2Is…
Abstract Number: 2588 • ACR Convergence 2025
Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates a Reduction in Gout Flares: Results from the Phase 3 DISSOLVE Studies
Angelo Gaffo¹, Herbert Baraf², Anand Patel³, Tuhina Neogi⁴, Rehan Azeem⁵, Wesley DeHaan⁶, Ben Peace⁷, Hugues Santin-Janin⁸, Bhavisha Desai⁹ and Naomi Schlesinger¹⁰, ¹Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ²The Center for Rheumatology and Bone Research, Rheumatology, Wheaton, Maryland, USA; Division of Rheumatology, The George Washington University, Washington, DC, ³Conquest Research, Winter Park, FL, USA, Winter Park, FL, ⁴Boston University School of Medicine, Boston, MA, ⁵Global MACD, Sobi Inc., Waltham, MA, ⁶Sobi, Inc, Waltham, MA, ⁷Statistical Science, Sobi, Stockholm, Sweden, ⁸Sobi, BASEL, Switzerland, ⁹Sobi, Glastonbury, CT, ¹⁰Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT
Background/Purpose: Urate-lowering therapy is recommended to lower serum urate (sUA) and for long-term prevention of gout flares (FitzGerald et al. Arthritis Care Res (Hoboken) 2020;…
Abstract Number: 1125 • ACR Convergence 2025
Validation of an Allopurinol Dose Prediction Tool to Achieve Goal Serum Urate Among Patients with Gout
Brian Coburn¹, Daniel Wright², Jeff Newcomb³, Mary Brophy⁴, Anne Davis-Karim⁵, Ryan Ferguson⁴, Michael Pillinger⁶, Tuhina Neogi⁷, Paul Palevsky⁸, Bryant England³, James O'Dell³, Lisa Stamp⁹, Ted Mikuls³ and Joshua Baker¹⁰, ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²University of Otago, Dunedin, New Zealand, ³University of Nebraska Medical Center, Omaha, NE, ⁴VA Cooperative Studies Program Coordinating Center, Boston, MA, ⁵VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, ⁶New York University Grossman School of Medicine, New York,, NY, ⁷Boston University School of Medicine, Boston, MA, ⁸VA Pittsburgh Healthcare System, Pittsburgh, PA, ⁹University of Otago, Christchurch, Christchurch, New Zealand, ¹⁰University of Pennsylvania, Philadelphia, PA
Background/Purpose: Despite evidence-based recommendations, allopurinol dose escalation to goal serum urate (SU) is frequently suboptimal. The EasyAllo tool was developed to facilitate pre-planned allopurinol dose…
Abstract Number: 2105 • ACR Convergence 2025
Stratification for elevated urate identifies a pro-inflammatory synovial fluid proteome in knee osteoarthritis: a pilot study
Tuhina Neogi¹, Sayali Dhamne², Robert Terkeltaub³, Virginia Kraus⁴, Simon Dillon⁵ and Towia Libermann⁵, ¹Boston University School of Medicine, Boston, MA, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³Retired, San Diego, CA, ⁴Duke University, Durham, NC, ⁵Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: The causes of inflammation, pain fluctuations, and disease progression in osteoarthritis (OA) are not well understood. Soluble urate is a “danger signal”, and synovial…
Abstract Number: 1123 • ACR Convergence 2025
Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates Long Term Efficacy and Safety in Patients with Uncontrolled Gout: Results from the 24-week Double-blind Extension of the Phase 3 DISSOLVE I Study
Alan Kivitz¹, Atul Singhal², Anand Patel³, Rehan Azeem⁴, Ben Peace⁵, Bhavisha Desai⁶ and Herbert Baraf⁷, ¹Altoona Center for Clinical Research, Duncansville, PA, ²SouthWest Arthritis Research Group, Mesquite, TX, ³Conquest Research, Winter Park, FL, USA, Winter Park, FL, ⁴Global MACD, Sobi Inc., Waltham, MA, ⁵Statistical Science, Sobi, Stockholm, Sweden, ⁶Sobi, Glastonbury, CT, ⁷The Center for Rheumatology and Bone Research, Rheumatology, Wheaton, Maryland, USA; Division of Rheumatology, The George Washington University, Washington, DC
Background/Purpose: Uncontrolled gout (UG) occurs when serum uric acid (sUA) levels remain persistently elevated despite use of oral urate-lowering therapies and can result in progressively…
Abstract Number: 2007 • ACR Convergence 2025
Machine Learning-Based Prediction of Gout Onset in Individuals with Asymptomatic Hyperuricemia Using a Common Data Model
Min Jung Kim¹, Sang Min Lee², Jun Seok Kim², Borim Ryu² and Kichul Shin³, ¹Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, South Korea, ²Center for Data Science, Biomedical Research Institute, Seoul Metropolitan Government–Seoul National University Hospital Boramae Medical Center, Seoul, Republic of Korea, ³Seoul National University, Seoul, South Korea
Background/Purpose: Long-term hyperuricemia is essential for the development of gout. However, only 9.9% of individuals with asymptomatic hyperuricemia (AHU) develop gout within 10 years. Identifying…

1
2
3
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].